CMS Modified NCD 88 for Psoriasis Treatment Coverage, Effective March 7, 2026 — What Billing Teams Need to Know

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 88, the National Coverage Determination governing Medicare coverage of psoriasis treatment, effective March 7, 2026. Here's what changes for billing teams.

This update to the CMS psoriasis treatment coverage policy clarifies which treatment modalities qualify for reimbursement and sets firm documentation and duration limits on PUVA therapy. No specific CPT or HCPCS codes are listed in the policy document itself — a real frustration for billing teams trying to map this directly to charge capture. What the policy does give you is clear medical necessity criteria, a defined treatment sequence, and a hard default cap on covered treatment duration.

If your practice or facility bills for dermatology services involving phototherapy or photochemotherapy, this policy directly affects your claim submission process.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Treatment of Psoriasis — NCD 88
Policy Code	NCD 88
Change Type	Modified
Effective Date	March 7, 2026
Impact Level	Medium
Specialties Affected	Dermatology, Primary Care, Hospital Outpatient (phototherapy services)
Key Action	Confirm that PUVA therapy claims include documentation of prior treatment failure and are limited to 30 days unless improvement is separately documented

---

CMS Psoriasis Treatment Coverage Criteria and Medical Necessity Requirements 2026

NCD 88 is the National Coverage Determination governing Medicare coverage of psoriasis treatment. The policy recognizes psoriasis as a chronic skin disease and defines which treatment approaches Medicare considers covered — and in what order.

The coverage policy works in tiers. Medicare covers these conventional treatments without a prior treatment failure requirement:

#	Covered Indication Copy
1	Topical steroids and other topical drugs
2	Ultraviolet light therapy (actinotherapy)
3	Coal tar alone or in combination with ultraviolet B (UVB) light — known as the Goeckerman treatment

These are your first-line, covered-without-restriction treatments. If your patient is receiving any of the above and the claim is otherwise clean, you don't face the sequencing hurdle.

PUVA therapy is different. PUVA — psoralen plus ultraviolet A light — is a second-line treatment under this coverage policy. Medicare covers PUVA therapy only for intractable, disabling psoriasis that has not responded to conventional treatment. Both conditions must be met. Intractable alone isn't enough. The psoriasis must also be disabling, and prior conventional treatment must have failed.

The medical necessity bar here is real. "Intractable and disabling" is not interchangeable with "moderate" or "persistent." Your documentation needs to show the condition has meaningfully impaired the patient's function or quality of life — not just that it's present and bothersome.

The Medicare Administrative Contractor (MAC) is responsible for verifying that prior treatment failure is documented before paying for PUVA therapy. That's not a soft suggestion. If the MAC doesn't have that documentation, the claim won't pay. Build this into your intake and authorization workflow now, before the effective date of March 7, 2026.

On the question of whether PUVA therapy requires formal prior authorization under NCD 88: the policy doesn't explicitly mandate a prior authorization process. But the MAC documentation requirement functions as a de facto review step. Treat it like prior auth — get the documentation in order before you submit the claim.

---

Coverage Indications at a Glance

---

CMS Psoriasis PUVA Therapy Billing Guidelines and Action Items 2026

The practical billing implications of this policy come down to three things: documentation sequencing, duration limits, and reimbursement caps. Here's what your team needs to do.

1. Audit your PUVA therapy claims for prior treatment failure documentation before March 7, 2026.

Pull any active or upcoming PUVA therapy cases now. Confirm each patient record shows documented failure of at least one conventional treatment — topical steroids, actinotherapy, coal tar, or Goeckerman. If that documentation isn't in the chart, the claim is at risk. Get it there before you submit.

2. Flag the 30-day treatment duration limit in your billing system.

The default coverage for PUVA therapy runs 30 days. After 30 days, you need documented improvement in the patient's condition to support continued reimbursement. Set a workflow trigger at day 25 so your clinical team has time to document the response before you hit the wall.

3. Verify reimbursement rates against other photochemotherapy services.

NCD 88 caps PUVA therapy reimbursement at amounts paid for other types of photochemotherapy. Check your fee schedule and make sure your charge capture reflects this ceiling. If you're submitting at a higher rate, expect a downward adjustment or a claim denial.

4. Confirm your MAC's documentation requirements and submission preferences.

The policy gives MAC contractors discretion in how they verify prior treatment failure. Contact your MAC directly — or check their local coverage determination (LCD) publications — to confirm what documentation format they expect. A letter of medical necessity from the treating dermatologist is standard, but some MACs have specific templates or clinical review processes.

5. Review your psoriasis billing workflows for "incident to" billing alignment.

NCD 88 lists both "Physicians' Services" and "Incident to a Physician's Professional Service" as applicable benefit categories. If mid-level providers in your practice are administering phototherapy services, confirm your incident-to billing guidelines are tight. The supervising physician requirements under incident-to rules apply here. A gap in supervision documentation creates a different kind of claim denial exposure.

6. Brief your dermatology team on the disabling/intractable standard.

This is the one billing teams can't fix alone. The clinical team needs to understand that "disabling" is a meaningful threshold, not a checkbox. If the treating physician isn't documenting how the psoriasis impairs the patient's daily function, you don't have a medical necessity case. Hold a short alignment meeting before the March 7, 2026 effective date.

---

CPT, HCPCS, and ICD-10 Codes for Psoriasis Treatment Under NCD 88

No Codes Listed in NCD 88 Policy Document

The NCD 88 policy document does not specify CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for older NCD frameworks that predate standardized code mapping, but it creates real work for your psoriasis billing team.

You'll need to identify the applicable codes through your MAC's LCD publications and your practice management system's crosswalk tools. The relevant procedure code categories to research include photochemotherapy (PUVA), actinotherapy/UVB phototherapy, and any associated office or facility visit codes for dermatology.

For ICD-10-CM, psoriasis diagnosis coding falls under the L40.x code range. Common codes in this range include plaque psoriasis, guttate psoriasis, psoriatic arthropathy, and pustular psoriasis variants. The specific ICD-10 code on the claim needs to align with the documented clinical presentation — and for PUVA claims, a code that reflects the severity and disabling nature of the condition will support your medical necessity argument.

If your billing team is unsure how to map this policy to your specific code set, loop in your compliance officer or billing consultant before the effective date. The absence of explicit codes in the NCD doesn't reduce your denial risk — it shifts the mapping responsibility to you.

---

What the Absence of Codes Means for Your Psoriasis Billing

This is worth stating plainly: a coverage policy that sets clear medical necessity criteria but lists no procedure codes puts the translation burden entirely on your billing team. That's a risk factor.

When your MAC audits a PUVA therapy claim, they'll apply NCD 88's criteria regardless of what code you submitted. If the code you used doesn't clearly map to photochemotherapy — or if the claim doesn't include supporting diagnosis codes that reflect intractable, disabling psoriasis — you're exposed to claim denial even if the clinical care was appropriate.

The right move is to identify how your MAC has operationalized NCD 88 in its local coverage determination publications. LCDs often fill the code-mapping gap that NCDs leave open. Check the CMS LCD database for your MAC's current LCD on phototherapy and photochemotherapy services.

---